Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on March 15, 2023. The Company is a biopharmaceutical entity incorporated in Delaware, with its principal executive offices in Bothell, WA. Its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure rather than financial performance data.
Material Changes
No material financial changes or operational events were reported in this filing. The document serves solely to disclose a public communication made by management.
Management Commentary and Disclosure
Under Item 7.01 (Regulation FD Disclosure), the Company announced the publication of a recorded interview with Dr. Sam Lee, Co-Chief Executive Officer. The interview covers:
- The Company's influenza, HCV, and COVID-19 programs.
- Details regarding its drug development platform.
- General developments in the biopharmaceutical industry.
A transcript of this interview is included as Exhibit 99.1. The Company explicitly states that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Transcript of Interview with Dr. Sam Lee) for specific details on drug development timelines and program status.
- Verify the Company's current cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the influenza, HCV, and COVID-19 programs mentioned in the interview.